Posts

A sleeker facial recognition technology tested on Miche...

Many people are familiar with facial recognition systems that unlock smartphones...

Welch Foundation supports Johnson-Winters’ TB research

With a $300,000 grant, the Welch Foundation is supporting University of Texas at...

Single-port robotic surgery is making its debut in the ...

Huntsman Cancer Institute at the University of Utah (the U) proudly introduces t...

Scientists mix and match properties to make new superco...

Tokyo, Japan – Researchers from Tokyo Metropolitan University have created a new...

Researchers identify protein linked to metastasis in pa...

Pancreatic cancer is the No. 3 cause of cancer-related deaths in the United Stat...

As England’s virus hospitalisations surge flu vaccines ...

England evaluates vaccine procurement and pandemic preparedness, whilst Moderna’...

Scottish company secures £4.2m to advance 3D-printed mi...

Carcinotech has gained funding to enter the North American market with the compa...

LimmaTech secures funding for vaccine technology develo...

LimmaTech announced the closing of a second round of its Series A financing, sec...

Biosyngen’s liver cancer therapy receives fast track de...

The US Food and Drug Administration (FDA) has granted fast track designation (FT...

Sanofi backs development of Graviton’s treatments for s...

Graviton Bioscience has secured a strategic investment from Sanofi to propel the...

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric di...

The US FDA has granted rare paediatric disease (RPD) designation for Tyra Biosci...

Keytruda remains Merck & Co’s biggest 2023 success stor...

Merck & Co (MSD) has reported a 1% revenue increase from 2022, and may face setb...

BMS reports 2% revenue loss in 2023 after Revlimid gene...

Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses ...

IGC Pharma heads towards a Phase I study for Alzheimer’...

With TGR-63 advancing towards the clinical stage, IGC Pharma is tackling differe...

AbbVie wins UK NICE endorsement for subcutaneous Tepkin...

AbbVie’s Tepkinly has been recommended for the treatment of relapsed or refracto...

STAT+: Medicare Advantage insurers face slight proposed...

The government wants to cut the average benchmark payments for 2025 Medicare Adv...